Clinical Research Directory

Inclusion Criteria: 1. Females aged 45-70 years during the menopausal transition or postmenopausal period. 2. Presence of at least one moderate-to-severe (score ≥ 2) symptom of GSM, including vulvovaginal dryness, or vulvovaginal itching/irritation, or vulvovaginal burning/pain, or dyspareunia, or dysuria/urinary frequency/urgency. 3. Willing to participate in this trial and sign a written informed consent form. Exclusion Criteria: 1. Acute or recurrent genitourinary infection. 2. Acute or chronic dermatosis of the vulva or vagina. 3. A grade 3 or higher degree of prolapse according to the Pelvic Organ Prolapse Quantification (POP-Q) system. 4. Unexplained abnormal uterine bleeding. 5. Ovarian/adnexal mass ≥ 4 cm, or adenomyosis, or adenomyoma/uterine myoma ≥ 4 cm. 6. Breast Imaging Reporting and Data System (BI-RADS) classification of breast ultrasound ≥ 4. 7. Presence of precancerous lesions or diagnosed malignancy. 8. Liver or kidney function indicators (ALT, AST, Urea, Cr) exceeding the upper limits of reference ranges upon repeated testing. 9. Severe primary diseases of the nervous, circulatory, respiratory, digestive, urinary or hematopoietic systems; or mental diseases; 10. Known allergy to any specific ingredient of the trial drugs. 11. Systemic hormone therapy within the past 2 months. 12. Application of vaginal moisturizers, lubricants, hormone preparations, or alternative therapies for GSM within the past month. 13. Current participation in another clinical trial or participation in another trial within the past month. 14. Unwillingness to discontinue the use of moisturizers, lubricants, or any form of hormonal drugs during the trial. 15. Other conditions deemed unsuitable for participation by the investigators.